摘要
1文献来源Novello S, Kowalski DM, Luft A, et al.Pembrolizumab plus chemotherapy in squamous nonsmall-cell lung cancer:5-year update of the phaseⅢKEYNOTE-407 study[J]. J Clin Oncol,2023,41(11):1999-2006.2证据水平1b。3背景对全球性随机Ⅲ期KEYNOTE-407研究的初步分析表明,与安慰剂联合化疗相比。
作者
刘嘉淇
梅世琪
周清
LIU Jia-qi;MEI Shi-qi;ZHOU Qing(Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China)
出处
《循证医学》
2023年第4期197-202,共6页
The Journal of Evidence-Based Medicine
关键词
非小细胞肺癌
总生存期
无进展生存期
长期生存
帕博利珠单抗
化疗
non⁃small cell lung cancer
overall survival
progression⁃free survival
long⁃term survival
pembrolizumab
chemotherapy
